Once you engage with just one of these videos, the algorithm floods your feed with more, Sharp explains
Temperature Fluctuations: Your refrigerator isn't a uniformly cold box
Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
5.1 Mechanism of intranasal delivery Since William Frey II proposed intranasal administration in 1991 (Frey, 1991), this technique has emerged as a novel, non-invasive delivery system, bypassing the BBB and the systemic first-pass effect, allowing rapid onset of action
including PIONEER 15, 7 and 8, a total of 5657 patients were included in the analysis
Should the scale be moving already
